Demographics |
no previous CAD |
previous CAD |
p |
| |
n=1452 |
n=1049 |
|
| Age |
66.7±10.8 |
69.5±10.5 |
<0.0001 |
| Height |
170.6±9.6 |
171.3±8.7 |
0.06 |
| Body weight |
81.9±16.8 |
81.97±14.99 |
0.86 |
| Abdomen circumference |
98.5±13.5 |
99.6±13.6 |
0.13 |
| BMI |
28.1±4.9 |
27.9±4.6 |
0.54 |
| Male Sex |
772 (53.8%) |
767 (73.8%) |
<0.0001 |
| Risk factors/concomitant diseases |
| Hypertension |
1015 (69.9%) |
817 (77.9%) |
<0.0001 |
| Dyslipidemia |
627 (43.2%) |
688 (65.6%) |
<0.0001 |
| Diabetes mellitus |
284 (19.6%) |
292 (27.8%) |
<0.0001 |
| COPD |
116 (8.0%) |
99 (9.4%) |
0.219 |
| Renal impairement |
60 (4.1%) |
80 (7.6%) |
<0.0001 |
| PAD |
64 (4.4%) |
100 (9.5%) |
<0.0001 |
| Previous myocardial infarction |
0 (0%) |
311 (29.6%) |
<0.0001 |
| Prior Stroke |
42 (2.9%) |
53 (5.1%) |
0.006 |
| Smoking |
415 (28.6%) |
303 (28.9%) |
0.893 |
Pack years (smokers only) |
29.2±23.0 |
30.53±32.1 |
0.6 |
| Symptoms |
| Classic AP |
598 (41.2%) |
541 (51.6%) |
<0.0001 |
| Atypical AP |
470 (32.4%) |
309 (29.5%) |
0.126 |
| Exertionaldyspnea |
632 (43.5%) |
381 (36.3%) |
<0.0001 |
| Number of AP per week |
3.1±4 |
3.6±4.2 |
0.003 |
| Number of NTG-intake per week |
0.64±1.9 |
1.7±3.4 |
<0.0001 |
| Stress test (performed) |
|
|
|
| Bicycle-Stress ECG |
954 (65.7%) |
646 (61.6%) |
0.035 |
| Stress echocardiography |
123 (8.5%) |
76 (7.2%) |
0.295 |
| Scintigraphy |
115 (7.9%) |
86 (8.2%) |
0.823 |
| cMR |
20 (1.4%) |
11 (1.0%) |
0.584 |
| Any positive stress test |
567 (39.0%) |
382 (36.4%) |
0.182 |
| Medical therapy |
| Platelet inhibitors |
664 (45.7%) |
827 (78.8%) |
<0.0001 |
| Beta-blockers |
731 (50.3%9 |
785 (74.8%) |
<0.0001 |
| ACE-inhibitors |
535 (36.8%) |
530 (50.5%) |
<0.0001 |
| AT1-receptor blockers |
289 (19.9%) |
243 (23.2%) |
0.053 |
| Calcium antagonists |
260 (17.9%) |
237 (22.6%) |
0.004 |
| Nitrates |
| Long-acting |
71 (4.9%) |
198 (18.9%) |
<0.0001 |
| Short-acting |
111 (7.6%) |
194 (18.5%) |
<0.0001 |
| NTG spray or sublingugal capsule |
120 (8.2%) |
210 (20%) |
<0.0001 |
| Statins |
406 (28%) |
762 (72.6%) |
<0.0001 |
| CAD (new or progression of known disease) |
240 (16.5%) |
892 (85%) |
<0.0001 |
